Torrent Pharmaceuticals The flagship company of the Torrent Group, Torrent Pharmaceuticals Limited is a major player in the Indian pharmaceuticals sector with the vision of becoming a global entity. Torrent Pharma enjoys dominance in the niche therapeutic areas like, cardiovascular and central nervous system, gastro-intestinal, pain management and oral anti-diabetic segments. Torrent Pharma owes its success in the domestic market to its thrust on frontline research, strategic marketing and world-class manufacturing. It is among the largest spenders on R&D and has set up one of the most advanced research centers in the country at an investment of Rs. 200 crores so far. It has discovered and patented the AGE (Advanced Glycosylation End Product) Breaker Compound which has potential to treat heart diseases and diabetes related vascular complications. Its manufacturing facilities have received quality certifications from various international regulatory authorities. It is this success that Torrent Pharma attempts to replicate in the international market now. It has already established fully-owned subsidiaries in Australia , Brazil , Germany , Japan , Mexico , Philippines Russia and USA and has over 1000 product registrations in more than 50 countries worldwide.
Torrent Pharmaceuticals Recruiting For Following:
Qualification: M.Pharma
Experience : 01-06+years
Role: Clinical research Scientist
Job Location: Ahmedabad
Interested Candidates may share their CVs on vilshashah@torrentpharma.com
Job Description
-Feasibility assessment/ new product evaluation
-Literature review and BA/BE study designing
-BE Study Monitoring
-Preparation of documents for regulatory submission (i.e BENOC, Import license application etc.)
-Establishment and maintenance of study documents
-Document preparation for dossier submission (i.e clinical overview, non-clinical overview, summery tables etc.)
-Review of BE study documents i.e protocol, reports, ICF etc.
-Preparation/review of medical write up
-Coordination for serious adverse event reporting and safety update to Regulatory agency.
No comments:
Post a Comment